{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:06:36Z","timestamp":1791331596146,"version":"4.3.1"},"reference-count":47,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2021-1058"],"award-info":[{"award-number":["075-15-2021-1058"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a devastating neurodegenerative disease caused by mutations in the SMN1 gene. Existing therapies demonstrate positive results on SMA patients but still might be ameliorated in efficacy and price. In the presented study we designed antisense oligonucleotides (AONs), targeting intronic splicing silencer sites, some were modified with 2\u2032-O-methyl, others with LNA. The AONs have been extensively tested in different concentrations, both individually and combined, in order to effectively target the ISS-N1 and A+100G splicing silencer regions in intron 7 of the SMN2 gene. By treating SMA-cultured fibroblasts with certain AONs, we discovered a remarkable increase in the levels of full-length SMN transcripts and the number of nuclear gems. This increase was observed to be dose-dependent and reached levels comparable to those found in healthy cells. When added to cells together, most of the tested molecules showed a remarkable synergistic effect in correcting splicing. Through our research, we have discovered that the impact of oligonucleotides is greatly influenced by their length, sequence, and pattern of modification.<\/jats:p>","DOI":"10.3390\/biomedicines11113071","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T01:56:29Z","timestamp":1700099789000},"page":"3071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of 2\u2032-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells"],"prefix":"10.3390","volume":"11","author":[{"given":"Marianna","family":"Maretina","sequence":"first","affiliation":[{"name":"Department of Genomic Medicine Named after V.S. Baranov, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arina","family":"Il\u2019ina","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Saint Petersburg State University, Universitetskaya Embankment 7\u20139, 199034 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Egorova","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine Named after V.S. Baranov, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-4504","authenticated-orcid":false,"given":"Andrey","family":"Glotov","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine Named after V.S. Baranov, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-2423","authenticated-orcid":false,"given":"Anton","family":"Kiselev","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine Named after V.S. Baranov, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00439-002-0828-x","article-title":"Genetic testing and risk assessment for spinal muscular atrophy (SMA)","volume":"111","author":"Ogino","year":"2002","journal-title":"Hum. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: Clinical classification and disease heterogeneity","volume":"22","author":"Russman","year":"2007","journal-title":"J. Child Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jmg.2008.057950","article-title":"Congenital heart disease is a feature of severe infantile spinal muscular atrophy","volume":"45","author":"Heller","year":"2008","journal-title":"J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: A changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Butchbach, M.E.R. (2021). Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157896"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.spen.2006.06.008","article-title":"Spinal Muscular Atrophy: From Gene to Therapy","volume":"13","author":"Wirth","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1389202919666180101154916","article-title":"Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates","volume":"19","author":"Maretina","year":"2018","journal-title":"Curr. Genom."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zheleznyakova, G.Y., Nilsson, E.K., Kiselev, A.V., Maretina, M.A., Tishchenko, L.I., Fredriksson, R., Baranov, V.S., and Schi\u00f6th, H.B. (2015). Methylation levels of SLC23A2 and NCOR2 genes correlate with spinal muscular atrophy severity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121964"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","article-title":"The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Crawford, T.O., Paushkin, S.V., Kobayashi, D.T., Forrest, S.J., Joyce, C.L., Finkel, R.S., Kaufmann, P., Swoboda, K.J., Tiziano, D., and Lomastro, R. (2012). Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033572"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Maretina, M., Egorova, A., Lanko, K., Baranov, V., and Kiselev, A. (2022). Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy. Genes, 13.","DOI":"10.3390\/genes13101911"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Al-hilal, H., Maretina, M., Egorova, A., Glotov, A., and Kiselev, A. (2023). Quantification of the Number of Nuclear Gems as a Potential Biomarker for Spinal Muscular Atrophy. Preprints, 2023091527.","DOI":"10.20944\/preprints202309.1527.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal Injections in Children with Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience","volume":"31","author":"Swoboda","year":"2016","journal-title":"J. Child Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263310552097398","DOI":"10.1177\/2633105520973985","article-title":"The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy","volume":"15","author":"Singh","year":"2020","journal-title":"Neurosci. Insights"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kray, K.M., McGovern, V.L., Chugh, D., Arnold, W.D., and Burghes, A.H.M. (2021). Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic \u22067SMA mice. Neurobiol. Dis., 159.","DOI":"10.1016\/j.nbd.2021.105488"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mirea, A., Shelby, E.-S., Axente, M., Badina, M., Padure, L., Leanca, M., Dima, V., and Sporea, C. (2021). Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235540"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4161\/rna.6.3.8723","article-title":"A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy","volume":"6","author":"Singh","year":"2009","journal-title":"RNA Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense Masking of an hnRNP A1\/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","article-title":"A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse","volume":"21","author":"Porensky","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23271","DOI":"10.1074\/jbc.M200851200","article-title":"Identification of a cis-acting element for the regulation of SMN exon 7 splicing","volume":"277","author":"Miyajima","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1073\/pnas.0700343104","article-title":"An intronic element contributes to splicing repression in spinal muscular atrophy","volume":"104","author":"Kashima","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1093\/nar\/gkt609","article-title":"An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy","volume":"41","author":"Singh","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45476","DOI":"10.1074\/jbc.M107632200","article-title":"Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3\u2032 Splice Site Pairing","volume":"276","author":"Lim","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/mt.2013.276","article-title":"Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene","volume":"22","author":"Pao","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The Medicinal Chemistry of Therapeutic Oligonucleotides","volume":"59","author":"Seth","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13670-020-00341-7","article-title":"Antisense Oligonucleotide Therapeutics for Neurodegenerative Disorders","volume":"11","author":"Testa","year":"2022","journal-title":"Curr. Geriatr. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","article-title":"LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts","volume":"7","author":"Touznik","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-021-00127-2","article-title":"Small activating RNAs lead the charge to turn up gene expression","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.23868\/gc120584","article-title":"Neural differentiation of patient-specific induced pluripotent stem cells from patients with a hereditary form of spinal muscular atrophy","volume":"11","author":"Valetdinova","year":"2016","journal-title":"Genes Cells"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zheleznyakova, G.Y., Kiselev, A.V., Vakharlovsky, V.G., Rask-Andersen, M., Chavan, R., Egorova, A.A., Schi\u00f6th, H.B., and Baranov, V.S. (2011). Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III. BMC Med. Genet., 12.","DOI":"10.1186\/1471-2350-12-96"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/mt.2016.145","article-title":"Optimization of morpholino antisense oligonucleotides targeting the intronic repressor element1 in spinal muscular atrophy","volume":"24","author":"Osman","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","article-title":"A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy","volume":"26","author":"Wu","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/nar\/16.8.3209","article-title":"Physicochemical properties of phospborothioate oligodeoxynucleotides","volume":"16","author":"Stein","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/nar\/gkh516","article-title":"2\u2032-O-methyl-modified phoshorothioate antisense oligonucleotides have reduced non-specific effects in vitro","volume":"32","author":"Yoo","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jgm.1288","article-title":"In vivo comparison of 2\u2032- O -methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping","volume":"11","author":"Heemskerk","year":"2009","journal-title":"J. Gene Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.omtn.2017.09.002","article-title":"Rational Design of Short Locked Nucleic Acid-Modified 2\u2032-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro","volume":"9","author":"Le","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","article-title":"Design of antisense oligonucleotides stabilized by locked nucleic acids","volume":"30","author":"Kurreck","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"13233","DOI":"10.1021\/bi0485732","article-title":"LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA","volume":"43","author":"Vester","year":"2004","journal-title":"Biochemistry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1093\/nar\/gku512","article-title":"Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro","volume":"42","author":"Shimo","year":"2014","journal-title":"Nucleic Acids Res."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/3071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:23:53Z","timestamp":1760131433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/3071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["biomedicines11113071"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11113071","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}